SB 297006 may be used to study CCR3-mediated cell signaling in asthma models.
Biochem/physiol Actions
CCR3 Antagonist
SB 297006 inhibits the recruitment and migration of eosinophils in allergen models of models. It suppresses the Th2-mediated eosinophil infiltration in the airways.[1][2]
SB-297006 is a potent, selective CCR-3 antagonist (IC50 = 60 nM). The compound blocked CCR3 agonist-induced calcium mobilization in CCR3 expressing cells with the following IC50 values: eotaxin, 210 nM; eotaxin-2, 90 nM and MCP4, 80 nM.
Features and Benefits
This compound is featured on the Chemokine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Annual review of pharmacology and toxicology, 42, 81-98 (2002-01-25)
Cytokines play a critical role in orchestrating and perpetuating inflammation in asthmatic airways and several specific cytokine and chemokine inhibitors are now in development for the treatment of asthma. Inhibition of IL-4 with soluble IL-4 receptors has shown promising early
Expert opinion on therapeutic patents, 19(8), 1109-1132 (2009-07-30)
Since the mid-1990s, there has been significant effort invested in the discovery and clinical development of CC chemokine receptor-3 (CCR3) antagonists as potential therapeutics for airway disease. A patent literature review is presented of small molecule CCR3 antagonists comprising the
We offer many products related to chemokine receptors for your research needs.
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
